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Introduction:
Haemophilia A (HMA) is an X-linked bleeding disorder caused by
reduced levels of the coagulation factor VIII (FVIII) due to alterations in
the F8 gene. Decreased levels of FVIII coagulant activity (FVIII:C) leads
to a loss of clotting activity and consequent bleeding (predominantly
into joins, muscles and inner organs). The severity of HMA ranges from
mild (5-30% FVIII:C) to moderate (2-5% FVIII:C) to severe (<1% FVIII:C).
During the last five years, we have found four novel variants identified
in five index patients with no family history of HMA.
Methodology:
Analysis of the F8 gene was performed in five index patients (one female from a family
without previous molecular studies, index case not available), using genomic DNA
extracted from peripheral EDTA blood samples and specific PCR for F8 exons, followed by
Sanger sequencing. F8 IVS22 and IVS1 inversions were excluded in severe HMA cases.
Bioinformatics analysis was performed with several pathogenicity prediction tools
(Alamut Visual, VarSome, VEP and Human Splicing Finder).
Figure 1. Electropherogram obtained from direct
nucleotide sequencing of F8 exon 18 (forward
primer) showing F8 c.5836G>T p.(Asp1946Tyr)
variant.
Results:
F8 variant analysis allowed identification of three frameshift and one
missense variants: c.1060_1061delCT, c.3561dupT and c.4804delC
detected in families presenting severe HMA; c.5836G>T variant was
identified in two unrelated patients with a mild phenotype (Table 1;
Figures 1-4). None of these variants had been previously reported.
Discussion:
In the three patients with severe HMA, three different novel F8 variants were identified: c.1060_1061delCT, p.(Leu354Thrfs*5) (Fig. 2), c.3561dupT,
p.(Pro1188Serfs*10) (Fig. 3) and c.4804delC, p.(Gln1602Lysfs*19) (Fig. 4). All these variants create a frameshift, leading to a premature termination codon and
presumably resulting in non-functional truncated proteins, confirming the patient’s phenotypes.
The novel F8 missense variant c.5836G>T, p.(Asp1946Tyr) (Fig. 1) was identified in two unrelated patients, both with mild HMA. The Asp1946 is a highly
conserved amino acid in the FVIII protein. Additionally, physicochemical properties between Asp and Tyr are significantly different (while Asp is a small,
negatively charged, and polar, Tyr is an hydrophobic, aromatic amino acid) and in silico analysis classified it as pathogenic due to the amino acid substitution.
According to in silico analysis, this variant can also disturb the normal mRNA splicing process due to the creation of a new donor splice site (Figure 5). RNA
studies and other functional assays are essential in order to establish this variant clinical significance.
Identification of novel pathogenic F8 variants in HMA patients allows genotype-phenotype correlations, appropriate genetic counseling and new knowledge
about the molecular bases of this pathology.
Figure 3. Electropherogram obtained from direct
nucleotide sequencing of F8 exon 14 (forward
primer) showing F8 c.3561dupT p.(Pro1188Serfs*10)
variant.
Figure 2. Electropherogram obtained from direct
nucleotide sequencing of F8 exon 8 (forward primer)
showing F8 c.1060_1061delCT p.(Leu354Thrfs*5)
variant. Results from a female carrier.
Figure 4. Electropherogram obtained from direct
nucleotide sequencing of F8 exon 14 (forward
primer) showing c.4804delC p.(Gln1602Lysfs*19)
variant.
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Table 1. Novel F8 variants identified.
P1
delCT
P2 P3
delC
P4
wild type wild type
Figure 5. Splicing effect predicted by Human Splicing Finder for the novel F8 variant c.5836G>T, p.(Asp1946Tyr)
dupT
Patient Variant type HMA clinicalphenotype
F8 
location
Nucleotide change Amino acid change
(NM_000132.3) (NP_000123.1)
P1
Missense Mild Exon 18 c.5836G>T (Fig. 1) p.(Asp1946Tyr)
P2
P3
Frameshift Severe
Exon 8 c.1060_1061delCT (Fig.2) p.(Leu354Thrfs*5)
P4
Exon 14
c.3561dupT (Fig.3) p.(Pro1188Serfs*10)
P5 c.4804delC (Fig.4) p.(Gln1602Lysfs*19)
wild type wild type
